Cargando…

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts

It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linch, Stefanie N, Redmond, William L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091104/ https://www.ncbi.nlm.nih.gov/pubmed/25050194 http://dx.doi.org/10.4161/onci.28245

Ejemplares similares

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

‘Hardcore’ OX40(+) immunosuppressive regulatory T cells in hepatic cirrhosis and cancer
por: Piconese, Silvia, et al.
Publicado: (2014)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
por: Demaria, Sandra, et al.
Publicado: (2013)

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye
por: Msaouel, Pavlos, et al.
Publicado: (2020)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression
por: Basso, Daniela, et al.
Publicado: (2013)

Integration of omics: more than the sum of its parts
por: Buescher, Joerg Martin, et al.
Publicado: (2016)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade
por: Duraiswamy, Jaikumar, et al.
Publicado: (2013)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015)

Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators
por: Hatfield, Stephen M, et al.
Publicado: (2015)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Mixed Metals Toxicity: More than the Sum of Its Parts?
por: Spivey, Angela
Publicado: (2012)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Microtubule plus tips: A dynamic route to chromosomal instability
por: Stolz, Ailine, et al.
Publicado: (2014)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
por: DeGregorio, Michael, et al.
Publicado: (2012)

LNL-Carbazole Pincer Ligand: More than the Sum of Its Parts
por: Kleinhans, George, et al.
Publicado: (2023)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

Configural Gestalts remain nothing more than the sum of their parts in visual agnosia
por: de-Wit, Lee H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sre8vbaue55a4gkmjunirbs2v7